Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-18
2009-08-18
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S568000
Reexamination Certificate
active
07576077
ABSTRACT:
The present invention is directed to compounds of formula I:wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
REFERENCES:
patent: WO 01/12627 (2001-02-01), None
patent: WO 03/029210 (2003-04-01), None
patent: WO 03/053922 (2003-07-01), None
patent: WO 03/077918 (2003-09-01), None
patent: WO 2004/014370 (2004-02-01), None
patent: WO 2004/014881 (2004-02-01), None
patent: WO 2004/014902 (2004-02-01), None
patent: WO 2005/077345 (2005-08-01), None
patent: WO 2005/080356 (2005-09-01), None
Aiba et al., “Reduced Hippocampal Long-term Potentiation and Context-Specific Deficit in Associative Learning in mGluR1 Mutant Mice”, Cell vol. 79, p. 365- (1994).
Aiba et al., “Deficient Cerebellar Long-Term Depression and Impaired Motor Learning in mGluR1 Mutant Mice”, Cell vol. 79, p. 377- (1994).
Baskys, “Metabotropic receptors and “slow” excitatory actions of glutamate agonists in the hippocampus”, Trends in Neuroscience, vol. 15, p. 92- (1992).
Bashir et al., “zInduction of LTP in the hippcampus needs synaptic activation of glutamate metabotropic receptors”, Nature, vol. 363, p. 347- (1993).
Bordi and Ugolini, “Group I Metabotropic Glutamate Receptors: Implications for Brain Diseases”, Prog. Neurobiol. vol. 59, p. 55-79 (1999).
Bordi and Ugolini, “Involvement of mGluR5on acute nociceptive transmission”, Brain Res. vol. 871, p. 223-233 (1999).
Bortolotto et al., “A molecular switch activated by metabotropic glutamate receptors regulates induction of long-term potentiation”,Nature, vol. 368, p. 740- (1994).
Cunningham et al., “Excitatory Amino Acid Receptors: A gallery of new targets for Pharmacological Intervention”, Life Sci. vol. 54, p. 135-148 (1994).
Gasparini et al, “Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutics perspectives”, Curr. Opin. Pharmacol. vol. 2, p. 43-49 (2002).
Hollman et al, “Cloned Glutamate Receptors”, Ann. Rev. Neurosci. vol. 17, p. 31- (1994).
Holloway et al., “Lower Esophageal Sphincter Dysfunction in Gastroesphageal Reflux Disease”, Gastroenterol. Clin. N. Amer. vol. 19, p. 517-535 (1990).
Joly et al., “Molecular, Functional, and Pharmacological characterization of the Metabotropic Glutamate Receptor Type 5 Splice Variants: Comparison with mGluR1”, J. Neurosci. vol. 15, p. 3970-3981 (1995).
Knopfel et al., “Metabotropic Glutamate Receptors: Novel Targets for Drug Development”, J. Med. Chem. vol. 38, p. 1417-1426 (1995).
Meller et al., “Acute mechanical hyperalgesia is produced by coactivation of AMPA and Metabotropic glutamate receptors”, Neuroreport vol. 4, p. 879- (1993).
Minakami et al., “Molecular Cloning and the Functional Expression of Two Isoforms of Human Metabotropic Glutamate Receptor Subtype 5”, BBRC vol. 199, p. 1136- (1994).
Mittal et al., “Transient Lower Esophageal Sphincter Relaxation”, Gastroenterology vol. 109, p. 601-610 (1995).
Nakanishi, “Metabotropic Glutamate Receptors: Synaptic Transmission, Modulation, and Plasticity”, Neuron, vol. 13, p. 1031- (1994).
Neugerbauer, “Metabotropic glutamate receptors—important modulators of nociception and pain behavior”, Pain, vol. 98, p. 1-8 (2002).
Pin et al., “Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release inXenopusoocytes”, PNAS vol. 89, p. 10331-10335 (1992).
Pin et al., “Review: Neurotransmitter receptors I, The metabotropic Glutamate Receptors: Structure and Functions”, Neuropharmacology vol. 34, p. 1- (1995).
Schoepp et al., “Metabotropic glutamate receptors in brain function and pathology”, Trends Pharmacol. Sci. vol. 14, p. 13-20 (1993).
Schoepp, “Novel Functions for Subtypes of Metabotropic Glutamate Receptors”, Neurochem. Int. vol. 24 p. 439-449 (1994).
Spooren et al., “Novel allosteric antagonists shed light on mGlu5 receptors and CNS disorders”, Trends Pharmacol. Sci. vol. 22, p. 331-337 (2001).
Van Herwaarden et al., “Diagnosis of reflux disease”, Bailliere's Clin. Gastroenterol. vol. 14, p. 759-774 (2000).
Watkins et al., “Phenylglycine derivatives as antagonists of metabotropic glutamate receptors”, Trends Pharmacol. Sci. vol. 15, p. 33-36 (1994).
Edwards Louise
Isaac Methvin
Johansson Martin
Kers Annika
McLeod Don
Astrazeneca AB
Birch & Stewart Kolasch & Birch, LLP
Coleman Brenda L
LandOfFree
Fused heterocyclic compounds and their use as metabotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heterocyclic compounds and their use as metabotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic compounds and their use as metabotropic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4071790